Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactoferrin for Rhabdomyolysis-induced Injury in Rats
NCT06491394Phase 4Completed
- Sponsor
- Aswan University Hospital
- Start
- Nov 2024
- Primary completion
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lactoferrin in rhabdomyolysis (4 arms), sponsored by Aswan University Hospital. Primary endpoints: Nuclear factor erythroid 2-related factor 2 expression at 2 months, Adenosine monophosphate-activated protein kinase levels at 2 months and 1 more. Started Nov 2024; status: completed.
02
Drugs
lactoferrin
03
Conditions
rhabdomyolysis
Beyond the preview
Go deeper on NCT06491394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06491394.